Akums Drugs Q2 FY27 Unaudited Results: Standalone Profit ₹326 Crore, Consolidated Profit ₹1,146 Crore
Akums Drugs reported Q2 FY27 standalone profit of ₹326 crore and consolidated profit of ₹1,146 crore. For H1 FY27, standalone profit was ₹775 crore and consolidated profit was ₹2,155 crore. Mr. Sanjay Kumar was designated as Senior Management Personnel.
The substantial increase in profits and the designation of a key management personnel are material events that can significantly influence investor perception and stock performance.
The company reported significant year-on-year growth in both standalone and consolidated profits for the quarter and half-year ended September 30, 2026, indicating strong financial performance.
Akums Drugs and Pharmaceuticals Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a standalone profit after tax of ₹326.37 crore for the quarter, compared to ₹234.62 crore in the same period last year. For the half-year ended September 30, 2026, the standalone profit stood at ₹774.76 crore.
On a consolidated basis, the profit after tax for the quarter ended September 30, 2026, was ₹1,145.65 crore, a significant increase from ₹426.96 crore in the corresponding quarter of the previous year. The consolidated profit for the half-year ended September 30, 2026, was ₹2,155.43 crore.
The Board of Directors also approved the designation of Mr. Sanjay Kumar, President – Operations, as a Senior Management Personnel of the Company. The Board meeting commenced at 02:33 P.M. (IST) and concluded at 04:23 P.M. (IST) on November 02, 2026.
The company also provided details regarding a tax demand of ₹600.92 million for the block period from April 1, 2018, to March 12, 2025, against which an appeal has been filed. The company has deposited ₹9 million as an advance under protest during the quarter and a further ₹16.20 million post quarter-end.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.